Artelo Biosciences Expansion into $16.3B Glaucoma Market, Via Fully Funded Study, Highlights Multi-Platform Pipeline Strength

Three clinical programs, one core molecule, and a capital-efficient strategy position Artelo Biosciences for sustained growth beyond a single indicationBRISTOL, Tenn., March 25, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ: ARTL) is drawing increased attention following its expansion into the $16.3 billion glaucoma market through a fully funded investigator-sponsored clinical study—an announcement that underscores a broader story: a multi-platform biotech pipeline built for durability across se ...